{"disease":{"id":"recurrent-vulvovaginal-candidiasis-rvvc","name":"recurrent vulvovaginal candidiasis rvvc"},"drugs":{"marketed":[{"drug_id":"oteseconazole","indication_name":"Recurrent vulvovaginal candidiasis (RVVC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vivjoa","generic_name":"OTESECONAZOLE","company_name":"Mycovia Pharms","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"Azole Antifungal [EPC]","quality_score":58,"revenue":null,"mechanism":"Vivjoa works by inhibiting the enzyme Cytochrome P450 3A4, which is involved in the synthesis of ergosterol, a critical component of fungal cell membranes."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}